Literature DB >> 10404763

Case-control study of the frequency of thrombophilic disorders in couples with late foetal loss and no thrombotic antecedent--the Nîmes Obstetricians and Haematologists Study5 (NOHA5).

J C Gris1, I Quéré, F Monpeyroux, E Mercier, S Ripart-Neveu, M L Tailland, M Hoffet, J Berlan, J P Daurès, P Marès.   

Abstract

BACKGROUND: Women with familial thrombophilia have an increased risk of still birth. We postulated that the presence of asymptomatic risk factors for venous thrombosis might be a risk factor for late foetal loss.
METHODS: We performed a case-control study on the prevalence of heritable thrombophilic defects, of antiphospholipid-related markers and of the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with at least one episode of late unexplained foetal loss and in control women with successful pregnancies. Partners of cases and controls were also studied. Written conclusions of the pathological examination of the placentas, when available, were also reviewed.
RESULTS: We found at least one positive biological risk factor for venous thrombosis in 21.1% of the patients and in 3.9% of the controls (p < 10(-4)). In women, the crude odds ratio for still birth associated with any positive biological risk factor for venous thrombosis was 5.5, 95% confidence interval (95%CI) [3.4-9.0]. No difference was found between partners of cases and controls (5.2% and 4.7%). Using conditional logistic regression analysis, 4 adjusted risk factors for still birth remained: protein S deficiency, positive anti beta2 glycoprotein I IgG antibodies, positive anticardiolipin IgG antibodies and the factor V Leiden mutation. The C677T mutation in the MTHFR gene was not an individual risk factor but an homozygous genotype was strongly associated with the former 4 risk factors (16.8% of patients vs. 0.9% of controls). In women with such associations, still births always occurred in absence of folic acid supplementation during pregnancy. Available conclusions of pathological analysis of placentas were found to have a very high proportion of "maternal vascular disease of the placenta" in patients with at least one positive risk marker for thromboembolism, specially in case of association with the C677T MTHFR homozygous genotype, compared to patients with negative markers (p <10(-4)).
CONCLUSIONS: Late foetal loss, through placenta thrombosis, may sometimes be the consequence of a maternal multifactorial prothrombotic state associating traditional heritable or acquired thrombosis risk factors to conditions predisposing to an acute mild hyperhomocysteinaemia (coexistence of a genetic predisposition with late pregnancy-related increased folate needs).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404763

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

Review 1.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  The Normal anticoagulant system and risk of placental abruption: protein C, protein S and resistance to activated protein C.

Authors:  Cande V Ananth; Carl A Nath; Claire Philipp
Journal:  J Matern Fetal Neonatal Med       Date:  2010-03-24

4.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

5.  Antiphospholipid Syndrome during pregnancy: the state of the art.

Authors:  Fosca A F Di Prima; Oriana Valenti; Entela Hyseni; Elsa Giorgio; Marianna Faraci; Eliana Renda; Roberta De Domenico; Santo Monte
Journal:  J Prenat Med       Date:  2011-04

6.  The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans.

Authors:  Nurit Rosenberg; Mitsuru Murata; Yasuo Ikeda; Ohene Opare-Sem; Ariella Zivelin; Eli Geffen; Uri Seligsohn
Journal:  Am J Hum Genet       Date:  2002-01-04       Impact factor: 11.025

7.  Recurrent pregnancy loss and thrombophilia.

Authors:  Maristella D'Uva; Pierpaolo Di Micco; Ida Strina; Giuseppe De Placido
Journal:  J Clin Med Res       Date:  2010-02-26

8.  Risk for early pregnancy loss by factor XIII Val34Leu: the impact of fibrinogen concentration.

Authors:  Astrid Dossenbach-Glaninger; Mick van Trotsenburg; Christian Oberkanins; Johanna Atamaniuk
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

9.  Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome.

Authors:  Claire S Philipp; Ambarina S Faiz; Michele G Beckman; Althea Grant; Paula L Bockenstedt; John A Heit; Andra H James; Roshni Kulkarni; Marilyn J Manco-Johnson; Stephan Moll; Thomas L Ortel
Journal:  Thromb Res       Date:  2013-11-01       Impact factor: 3.944

10.  Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy.

Authors:  Maristella D'Uva; Pierpaolo Di Micco; Ida Strina; Antonio Ranieri; Carlo Alviggi; Antonio Mollo; Francesca Fabozzi; Lucia Cacciapuoti; Maria Teresa Scotto di Frega; Mariateresa Iannuzzo; Giuseppe De Placido
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.